Acrivon Therapeutics is leveraging its proprietary AP3 (Acrivon Predictive Precision Proteomics) Platform to develop precision oncology medicines. The platform utilizes phosphoproteomics-based ...

The CellScape™ Precise Spatial Proteomics platform is a cutting-edge imaging solution for quantitative in situ spatial phenotyping. The CellScape platform enables highly multiplexed spatial proteomics ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" ...

The installation of next-generation proteomics and multi-omics technology at the Baker Institute this month will provide ...

Signios Biosciences ("Signios Bio"), a science-first biotechnology company at the forefront of multiomics and AI-powered ...

Nautilus Biotechnology, Inc.’s NAUT share price has dipped by 10.19%, which has investors questioning if this is right time ...

Instead of assessing a sample by eye, a pathologist could use a spatial-proteomics platform to measure the amount of a protein in a square millimetre of tissue on a slide. “Measurement ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

Consumers can now book Molecular You's at-home blood test to access science-backed early disease risk detection and ...

Quantum-Si is a biotech star, with a 327% surge in stock price. Its proteomics platform and partnerships make it one to watch in 2025.

Researchers say findings provide compelling evidence underscoring the potential of electric-field molecular fingerprinting for minimally invasive disease detection.